Alnylam Pharmaceuticals 株価情報 (NASDAQ: ALNY)

最新ニュース Alnylam Pharmaceuticals (NASDAQ:ALNY) 株価情報

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Large Cap

News

Movers

ALNY

CVNA

FTAI

MSTR

RDDT

RIVN

過去1週間でこれらの10本の大型株は最も良いパフォーマンスを発揮しました。投資ポートフォリオには含まれていますか？Rivian Automotive, Inc. (NASDAQ:RIVN)の株は、同社が生産を単純化し、コストを削減し、フォルクスワーゲンとの 合弁事業を発表したという報告書に続き、先週30.04％急騰しました。

過去1週間の大型株を特集　米国市場での存在感は

Equities

Markets

AFRM

NVDA

TSLA

月曜日、米国の主要株価指数は反発しました。ダウ平均株価は0.7％以上の上昇で39,411.21ドルで終了し、一方でS&amp;P500は0.3％減の5,447.87ドルでした。ナスダックは約1.1％減の17,496.82でした。

Nvidiaが米国の主要株価指数を牽引　

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 4.18% since its last report. The company recently reported that it has 3.35 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737032452_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 7.96% on an annualized basis producing an average annual return of 19.36%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.31 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth $14,221.92 today based on a price of $258.27 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736802908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

WIIM

Alnylam Pharmaceuticals shares are trading higher. The company reported preliminary results.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.2, a high estimate of $400.00, and a low estimate of $296.00. This current average has increased by 2.93% from the previous average price target of $326.64. 
<img src="https://www.benzinga.com/files/images/story/2025/1736769643_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$310.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$329.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$371.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alnylam Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>A Deep Dive into Alnylam Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Alnylam Pharmaceuticals faced challenges, resulting in a decline of approximately -33.26% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -22.27%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -761.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.72%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 40.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

<ul>
<li>– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO&#xAE;, AMVUTTRA&#xAE;, GIVLAARI&#xAE;, and OXLUMO&#xAE;, Representing 33% Annual Growth –</li>
<li>– 2025 Combined Net Product Revenue Guidance&#x2A;&#x2A; of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability –</li>
<li>– Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth –</li>
</ul>

Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B–$2.25B, And Highlights Key Pipeline Goals

Bernstein analyst William Pickering maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and lowers the price target from $314 to $310.

Bernstein Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $310

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>), a company focused on developing drugs for <a target="_blank" href="https://www.benzinga.com/quote/DNLI" rel="noreferrer noopener">neurodegenerative diseases</a>.
The analyst highlights that Denali is developing a specialized transport vehicle (TV) platform to enhance the delivery of treatments across the blood-brain barrier.
It stands out from competitors with its promising potential for top-tier performance and scalability across different therapies and conditions.
The company&#8217;s lead program Tividenofusp alfa, an enzyme-replacement therapy for Hunter syndrome, shows promise as a best-in-class treatment, the analyst highlights.
William Blair has initiated with an Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/DNLI/analyst-ratings" rel="noreferrer noopener">fair value of $35 per share</a>.
The company has reached an agreement with the FDA on the requirements for accelerated approval and plans to submit a biologics license application <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40684612/denali-therapeutics-announces-successful-meeting-with-the-fda-and-plans-to-file-for-accelerated-ap" rel="noreferrer noopener">in early 2025</a>.
Insights gained from tividenofusp alfa may also simplify the development and approval process for future treatments targeting other lysosomal storage diseases, such as DNL126 for Sanfilippo syndrome type A.
Most recently, Denali Therapeutics initiated dosing in a global BEACON Phase 2a trial of BIIB122 (DNL151) for LRRK2-associated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42336987/denali-therapeutics-announces-first-participant-dosed-in-phase-2a-study-of-lrrk2-inhibitor-biib122" rel="noreferrer noopener">Parkinson&#8217;s disease</a>.
Denali&#8217;s market cap stands at $2.93 billion, with an enterprise value of $2.26 billion.
Compared to its peers in neuroscience, rare diseases, and platform biotech, its valuation is lower than some but higher than others, reflecting the strength of its pipeline and technology.
William Blair notes the potential for significant growth as Denali advances its assets, including tividenofusp, which might receive accelerated approval and priority review by late 2025.
If additional clinical data reduces risks associated with its TV-enabled approach, Denali could achieve valuations similar to companies like Avidity Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), Alnylam Pharmaceuticals, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), and Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>).
Price Action: DNLI stock is up 3.17% at $21.50 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/42788070/hedge-fund-giant-dan-loebs-pge-bet-beats-market" target="_blank" rel="noreferrer noopener">Hedge Fund Giant Dan Loeb&#8217;s PG&amp;E Bet Beats Market</a></li>
</ul>

Analyst Color

Biotech

Health Care

Initiation

General

BIIB

DNLI

IONS

RARE

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 9.26% on an annualized basis producing an average annual return of 17.63%. Currently, Alnylam Pharmaceuticals has a market capitalization of $29.99 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $22,842.13 today based on a price of $232.50 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735916410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 9.01% since its last report. The company recently reported that it has 3.39 million shares sold short, which is 3.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735047916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 4.97%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Alnylam Pharmaceuticals?

GIVLAARI Gains Nationwide Reimbursement In Canada For Treating Acute Hepatic Porphyria

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 11.51% on an annualized basis producing an average annual return of 19.9%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.00 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,877.12 today based on a price of $255.89 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733779840_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 19 unusual trades.
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued at $321,410.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $220.0 and $280.0 for Alnylam Pharmaceuticals, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Alnylam Pharmaceuticals stands at 355.17, with a total volume reaching 1,362.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Alnylam Pharmaceuticals, situated within the strike price corridor from $220.0 to $280.0, throughout the last 30 days.
<h3>Alnylam Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732563016_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$38.0</td>
<td>$35.6</td>
<td>$38.0</td>
<td>$220.00</td>
<td>$190.0K</td>
<td align="right">262</td>
<td align="right">50</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$20.9</td>
<td>$18.5</td>
<td>$19.0</td>
<td>$270.00</td>
<td>$127.3K</td>
<td align="right">601</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$28.0</td>
<td>$26.9</td>
<td>$28.0</td>
<td>$280.00</td>
<td>$120.4K</td>
<td align="right">312</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$28.3</td>
<td>$25.2</td>
<td>$28.3</td>
<td>$280.00</td>
<td>$107.5K</td>
<td align="right">312</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$27.5</td>
<td>$27.4</td>
<td>$27.5</td>
<td>$280.00</td>
<td>$82.5K</td>
<td align="right">312</td>
<td align="right">250</td>
</tr>
</tbody>
</table>

<h3>About Alnylam Pharmaceuticals</h3>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
After a thorough review of the options trading surrounding Alnylam Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Alnylam Pharmaceuticals</h3>
<ul>
<li>With a volume of 460,809, the price of ALNY is up 3.96% at $254.59. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 80 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Check Out What Whales Are Doing With ALNY

The FDA Has Alnylam Pharmaceuticals' Supplemental Marketing Application For Vutrisiran For ATTR Amyloidosis With Cardiomyopathy, Based On The Company's Use Of A Priority Review Voucher, FDA Has Set An Action Date Goal Of March 23, 2025

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 11 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $515,770, and 2 were calls, valued at $88,650.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $290.0 for Alnylam Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Alnylam Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Alnylam Pharmaceuticals's significant trades, within a strike price range of $210.0 to $290.0, over the past month.
<h3>Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732049153_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$240.00</td>
<td>$130.2K</td>
<td align="right">517</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.0</td>
<td>$3.5</td>
<td>$210.00</td>
<td>$62.6K</td>
<td align="right">170</td>
<td align="right">457</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$58.5</td>
<td>$55.9</td>
<td>$57.0</td>
<td>$290.00</td>
<td>$57.0K</td>
<td align="right">241</td>
<td align="right">40</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$54.0</td>
<td>$50.5</td>
<td>$54.0</td>
<td>$250.00</td>
<td>$54.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$50.1</td>
<td>$46.6</td>
<td>$48.1</td>
<td>$280.00</td>
<td>$52.9K</td>
<td align="right">395</td>
<td align="right">11</td>
</tr>
</tbody>
</table>

<h3>About Alnylam Pharmaceuticals</h3>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
In light of the recent options history for Alnylam Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Alnylam Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>What Analysts Are Saying About Alnylam Pharmaceuticals</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $350.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Alnylam Pharmaceuticals, targeting a price of $384. 
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $296. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $400. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $300. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Alnylam Pharmaceuticals, maintaining a target price of $371. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Alnylam Pharmaceuticals

Piper Sandler analyst Edward Tenthoff reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and maintains $296 price target.

Piper Sandler Reiterates Overweight on Alnylam Pharmaceuticals, Maintains $296 Price Target

<ul>
<li>Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months&nbsp;</li>
<li>At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 −</li>
<li>Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis −</li>
<li>Encouraging Safety and Tolerability Observed −</li>
<li>Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –</li>
</ul>

Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose

Alnylam Pharmaceuticals shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform.

Sees FY25 combined net product revenue guidance of $2.05B-$2.25B. "Alnylam's (ALNY) commercial and clinical achievements in 2024 position us very w...

Alnylam reports preliminary FY24 product revenues $1.646B, up 33% versus FY23

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), retaining the price target of $275.00. M...

Alnylam Pharma: Stable Growth and Balanced Outlook Justify Hold Rating

Alnylam sees 2024 net product revenues of over $1.6B, up 33% Y/Y

David Lebowitz, an analyst from Citi, maintained the Buy rating on Alnylam Pharma (ALNY – Research Report). The associated price target is $340.00....

Alnylam Pharma: Strong Financial Performance and Promising Growth Prospects

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of...

Alnylam Pharma's Strong Financial Performance and Growth Prospects Justify Buy Rating

TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $371.00. Ritu Baral ...

Alnylam Pharma's Strong Revenue Performance and Growth Potential Justifies 'Buy' Rating

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Strong Growth Prospects and Financial Performance Drive Buy Rating for Alnylam Pharma

After Alnylam (ALNY) CEO Yvonne Greenstreet presented at the JPMorgan Healthcare Conference, JPMorgan thinks the Street will "continue to debate to...

Alnylam positive reaction to guidance 'makes sense,' says JPMorgan

J.P. Morgan analyst Jessica Fye has maintained their neutral stance on ALNY stock, giving a Hold rating yesterday. Jessica Fye has given her Hold r...

Balanced Hold Rating on Alnylam Pharma Amid Promising Growth and Uncertainties

Raymond James analyst Gary Nachman reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $298.00. The ...

Alnylam Pharma (ALNY) Gets a Buy from Raymond James

Press Releases

Alnylam Canada Signs Letter of Intent from pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of AMVUTTRA® For The Treatment Of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis In Adults

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

GIVLAARI® (givosiran injection) Now Widely Reimbursed in Canada For the Treatment of Acute Hepatic Porphyria (AHP) in Adults

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

AbbVie

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

HC Wainwright & Co.

Needham

Bernstein

Piper Sandler

Raymond James

過去1週間でこれらの10本の大型株は最も良いパフォーマンスを発揮しました。投資ポートフォリオには含まれていますか？
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)の株は、同社が生産を単純化し、コストを削減し、フォルクスワーゲンとの <a href="https://www.benzinga.com//node/39497161" target="_blank" rel="noreferrer noopener">合弁事業を発表した</a>という報告書に続き、先週30.04％急騰しました。</li>
<li>Carnival Plc（NYSE:CUK）の株は、<a href="https://www.benzinga.com//node/39481992" target="_blank" rel="noreferrer noopener">予想を上回る第2四半期の決算</a>を受けた株価の持続的な強さにより17.78％上昇しました。</li>
<li>FedEx Corporation（NYSE:FDX）の株は先週、予想を上回る第4四半期の財務諸表と業績予測により17.51％急騰しました。さらに、同社は「2025年度に株式2.5十億ドルを自社株買いのために買い戻す見通し」としている<a href="https://www.benzinga.com//node/39504381" target="_blank" rel="noreferrer noopener">（リンク先PDF）</a>と発表しました。複数のアナリストが株価予測を引き上げました。<a href="https://www.benzinga.com//node/39509568" target="_blank" rel="noreferrer noopener">（リンク先PDF）</a></li>
<li>多くのアナリストが「強気」のレーティングを維持し、<a href="https://www.benzinga.com/quote/iot/analyst-ratings" target="_blank" rel="noreferrer noopener">価格ターゲットを47ドルに維持し</a>たことを受け、RBCキャピタルがアウトパフォーム評価を再確認したことから、Samsara Inc. （NYSE:IOT）の株価は16.37％上昇しました。</li>
<li>Suzano S.A.（NYSE:SUZ）の株は、同社がInternational Paper Co.（NYSE:IP）の買収を<a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">取りやめたと発表したこと</a>を受け、12.24％上昇しました。</li>
<li>Carvana Co.（NYSE:CVNA）の株は、6月初旬のWilliam Blair株44回目の年次グロース株式投資<a href="https://www.benzinga.com//node/39509401" target="_blank" rel="noreferrer noopener">カンファレンスで、自社の運営計画と資本構造を更新した後、11.93％上昇しました。</a></li>
<li>FTAI Aviation Ltd.（NASDAQ:FTAI）の株は先週11.55％上昇しました。</li>
<li>Reddit, Inc.（NYSE:RDDT）の株は、同社が<a href="https://www.benzinga.com//node/39494776" target="_blank" rel="noreferrer noopener">自動ウェブサイトスクレイピングをブロックする方針を発表したこと</a>を受け、11.08％急騰しました。</li>
<li>Mongodb Inc（NASDAQ:MDB）の株は、先週10.57％急騰しました。</li>
<li>Alnylam Pharmaceuticals, Inc.（NASDAQ:ALNY）の株は、同社がvutrisiranのHELIOS-B第3フェーズ試験のトップラインの結果を発表したことを受けて10.82％上昇しました。複数のアナリストが<a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">同社の株価予測を引き上げた</a>と発表しました。</li>
</ol>

月曜日、米国の主要株価指数は反発しました。ダウ平均株価は0.7％以上の上昇で39,411.21ドルで終了し、一方でS&amp;P500は0.3％減の5,447.87ドルでした。ナスダックは約1.1％減の17,496.82でした。
以下は、この日一日中小売トレーダーや投資家の関心を集めたトップ銘柄です。
Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
Nvidiaの株は6.68％減の118.11ドルで取引を終えました。株の日中の高値は124.46ドル、安値は118.04ドルでした。株の52週レンジは39.23ドルから140.76ドルの間です。この半導体企業はCEOのJen Huangが1億ドル以上の株式を売却した<a href="https://www.benzinga.com/markets/equities/24/06/39462808/semiconductor-nvidia-woes-deepen-nasdaq-100-slips-dow-rallies-bitcoin-sinks-to-60-400-whats-driv">売り勢の後</a>に、株価は訂正進入しました。
Affirm Holdings Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)
Affirmの株は12.82％上昇し、33.70ドルで取引を終了しました。株の日中の高値は34.13ドル、安値は30.77ドルでした。株の52週レンジは12.81ドルから52.48ドルの間です。ゴールドマン・サックスのアナリストWill NanceがAffirmの株式をBuy評価と42ドルの目標株価でカバーしました。
Carnival Corporation(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>)
Carnivalの株は1.99％上昇し、16.39ドルで取引を終了しました。その日の株の最高値は16.5ドル、最安値は16ドルでした。この株の52週レンジは10.84ドルから19.74ドルの間です。同社は火曜日に<a href="https://www.benzinga.com/general/entertainment/24/06/39464753/carnival-stock-in-strong-bullish-trend-ahead-of-q2-earnings-why-analyst-sees-multiyear-port">四半期決算</a>を発表する予定で、ウォール街は純利益20セント/株、売上高57億ドルを予想しています。
Alnylam Pharmaceuticals, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)
Alnylamの株は34.52％急騰し、222.90ドルで終了しました。株の日中の高値は231.64ドル、安値は209.23ドルでした。この株の52週レンジは141.98ドルから231.64ドルの間です。株価は同社が開発中のATTR心筋症向けのRNAi治療薬であるvutrisiranのHELIO-Bフェーズ3試験で<a href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s">良好な結果を発表した後</a>に上昇しました。
Tesla Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Teslaの株はわずか0.23％減の182.58ドルで取引を終了しました。株の日中の高値は188.8ドル、安値は182.55ドルでした。株の52週レンジは138.8ドルから299.29ドルの間です。Gary Blackが、Delaware州の裁判官が「Tornetta vs. Musk」事件で<a href="https://www.benzinga.com/news/24/06/39449373/tesla-bull-gary-black-slams-delaware-chancellors-judicial-activism-in-elon-musks-56b-pay-package-cas">司法活動を行ったと批判</a>しました。この事件は、TeslaのElon Muskが保有する560億ドルの報酬パッケージを争うものであり、司法の役割や立法の対応についての広範な議論を呼びました。
株価の予想動きとビジネスニュースのトップで、ベンジンガによる本日の取引に備えよ。
このストーリーは<a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>によって生成されたもので、<a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>によって編集されました。

Comments

Alnylam Pharmaceuticals

ニュース

最新ニュース Alnylam Pharmaceuticals (NASDAQ:ALNY) 株価情報

月曜日, 7 01, 2024

火曜日, 6 25, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル